If you or someone you know takes Elmiron for interstitial cystitis, you may have heard about potential eye symptoms. Medical reports have documented cases of pigmentary maculopathy—a condition that can cause vision changes—in long-term users. Building on decades of general health education, this page explains the plain-language facts about these recognized adverse events and what current reports say.
Elmiron (pentosan polysulfate sodium) is a medication approved for the relief of bladder pain or discomfort associated with interstitial cystitis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). However, long-term use of Elmiron has been linked to pigmentary changes in the retina, reported in the literature as pigmentary maculopathy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). This condition involves abnormal deposits of pigment in the macula, the central part of the retina responsible for sharp, detailed vision. Clinical presentation of pigmentary maculopathy often includes difficulty reading, slow adjustment to low or reduced light environments, and blurred vision (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). The visual consequences of these pigmentary changes are not fully characterized, but they may be irreversible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). The pharmacology of Elmiron involves its use as a synthetic sulfated polysaccharide, but the mechanistic pathways linking it to pigmentary maculopathy are not fully understood. While the etiology is unclear, cumulative dose appears to be a risk factor (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). Most reported cases of pigmentary maculopathy occurred after 3 years of use or longer, but cases have been seen with a shorter duration of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). This timeline between exposure and documented harm is critical for understanding risk.
The FDA Adverse Event Reporting System (FAERS) data show that maculopathy is the most frequently reported adverse event associated with Elmiron, with 1382 reports, followed by retinal pigmentation (607 reports) and pigmentary maculopathy (442 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:ELMIRON). Other related events include dry age-related macular degeneration (560 reports), macular degeneration (212 reports), and retinal dystrophy (141 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:ELMIRON). These data underscore the significance of retinal adverse effects in patients using Elmiron. Regarding the adequacy of warnings, the Elmiron label includes a Warnings section that specifically addresses retinal pigmentary changes (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). It recommends obtaining a detailed ophthalmologic history in all patients prior to starting treatment. For patients with pre-existing ophthalmologic conditions, a comprehensive baseline retinal examination, including color fundoscopic photography, ocular coherence tomography (OCT), and auto-fluorescence imaging, is recommended before starting therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). For all patients, a baseline retinal examination, including OCT and auto-fluorescence imaging, is suggested within six months of initiating treatment and periodically while continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). If pigmentary changes in the retina develop, the risks and benefits of continuing treatment should be re-evaluated, since these changes may be irreversible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593). Caution should be used in patients with retinal pigment changes from other causes, as examination findings may confound appropriate diagnosis, follow-up, and treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593).
For affected patients in Illinois, settlement-related considerations are relevant. The statute of limitations for filing a claim related to Elmiron pigmentary maculopathy in Illinois is governed by state law, which typically requires claims to be filed within a certain period from the date of injury or discovery of the injury. Given that pigmentary maculopathy may develop after years of Elmiron use, the timeline between exposure and documented harm is crucial. Patients who have used Elmiron for 3 years or longer and have developed visual symptoms such as difficulty reading, slow dark adaptation, or blurred vision should seek ophthalmologic evaluation. If diagnosed with pigmentary maculopathy, they may have a claim against the manufacturer for failure to adequately warn about this risk. The FAERS data indicate that visual impairment is reported in 150 cases, highlighting the potential for significant visual disability (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:ELMIRON). Settlement considerations may include compensation for medical expenses, vision loss, and pain and suffering. Patients should consult with a legal professional to understand the specific statute of limitations in Illinois, as it may vary based on the date of diagnosis or discovery of the link between Elmiron and their condition.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
The statute of limitations in Illinois for personal injury claims, including those related to Elmiron-induced pigmentary maculopathy, is generally two years from the date of injury or from when the injury was discovered or should have been discovered. Because pigmentary maculopathy may develop years after starting Elmiron, the discovery rule often applies, meaning the clock starts when the patient is diagnosed or becomes aware of the link between Elmiron and their vision problems. It is crucial to consult an attorney promptly to avoid missing the deadline.
To support a claim, you typically need documentation of Elmiron use (prescription records, pharmacy records), medical records confirming a diagnosis of pigmentary maculopathy (e.g., retinal examination, OCT, autofluorescence imaging), and evidence linking the condition to Elmiron, such as a timeline of use and symptom onset. Expert medical testimony may also be required. The FDA label and FAERS data (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:ELMIRON) can serve as supporting evidence that the manufacturer was aware of the risk.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Elmiron exposure and a related diagnosis may request an independent, no-cost eligibility review.
Request archival records or inquire about member-exclusive transition and benefit programs.